MedDataX Logo

Precise Diagnosis, Treatment and Prognostic Evaluation of Complicated Adrenal Tumor Diseases

NCT ID: NCT04529629

Last Updated: 2021-12-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-08-30

Study Completion Date

2041-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The adrenal gland is an important organ that produces life hormones. There are many types of adrenal tumors, which tend to occur in young adults and affect the whole body. It has the dual threat: hormone secretion and tumor metastasis. At present, there are four major dilemmas in the clinical diagnosis and treatment of adrenal tumors: 1) Pulse secretion of the hormones, which are affected by many factors; and the diagnostic value of single hormone is limited; 2) Traditional imaging cannot accurately reflect the characteristics of hormone secretion. The prognosis cannot be accurately predicted; 3) The molecular characteristics of tumor cells and the microenvironment are unclear, making it difficult to implement early diagnosis and precise treatment; 4) Traditional pathology cannot determine the nature and long-term prognosis of the tumor, which makes the treatment delay, and the disease prognosis is extremely poor. It threatens the lives of patients.

Starting from solving the above-mentioned key problems in the early stage, the research team has systematically established new clinical diagnostic technologies, hormone dynamic tests to accurately assess hormone secretion and segmented blood collection hormone determination technologies to accurately locate adrenal tumors; A series of important research results have been published in Science, Lancet Diabetes \& Endocrinology, Cell Research, etc To sum up, the goal of this research is improving the early diagnosis rate of complicated adrenal tumors especially in malignant tumors, developing the optimal treatment plan, avoiding unnecessary surgical treatment, improving the quality of life of patients, reducing mortality. This project will further integrate the adrenal cortex and medulla hormone mass spectrometry detection and the molecular markers of adrenal tumors through phenotypic, functional imaging, and molecular pathological evaluations, and built a sensitive drug screening platform that integrates visual drug response and molecular characteristics, thereby achieving precise diagnosis and treatment of complicated adrenal tumors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Complicated Adrenal Tumor Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

primary aldosteronism

surgery or drug

Intervention Type OTHER

pheochromocytoma and adrenocortical carcinoma need surgery and primary aldosteronism need drug according to the genetic results

pheochromocytoma

surgery or drug

Intervention Type OTHER

pheochromocytoma and adrenocortical carcinoma need surgery and primary aldosteronism need drug according to the genetic results

adrenocortical carcinoma

surgery or drug

Intervention Type OTHER

pheochromocytoma and adrenocortical carcinoma need surgery and primary aldosteronism need drug according to the genetic results

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

surgery or drug

pheochromocytoma and adrenocortical carcinoma need surgery and primary aldosteronism need drug according to the genetic results

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years old and ≤ 75 years
* Diagnosis of Patients with primary aldosteronism, pheochromocytoma, and cortical cancer
* Gender: males and females
* Provide written informed consent
* Satisfactory compliance

Exclusion Criteria

1. Patients with renal insufficiency (Cr\>2 times the upper limit of normal).
2. Patients with a history of liver cirrhosis.
3. Patients who are currently using corticosteroids.
4. Patients with cardiac insufficiency (NYHA cardiac function classification grade 3 and above or EF\<50%).
5. Patients with stroke and acute myocardial infarction in the past 6 months.
6. Patients during pregnancy and lactation
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shanghai Jiao Tong University School of Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Wang Weiqing

PhD, MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ruijin Hospital

Shanghai, Shanghai Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yiran Jiang, MD

Role: CONTACT

Phone: 8621-64370045

Email: [email protected]

Luming Wu, PhD

Role: CONTACT

Phone: 8621-64370045

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yiran Jiang

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CCEMD-2020-0825

Identifier Type: -

Identifier Source: org_study_id